No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMED240719P90000
- 0.05
- -0.25-83.33%
15min DelayClose Jul 16 15:09 ET
0.05High0.05Low
0.05Open0.30Pre Close4 Volume65 Open Interest90.00Strike Price20.00Turnover51.14%IV7.97%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0294Delta0.0154Gamma1954.80Leverage Ratio-0.0391Theta-0.0002Rho-57.43Eff Leverage0.0057Vega
Intraday
- 5D
- Daily
News
Here's Why Amedisys (AMED) Is a Strong Momentum Stock
NASDAQ New 52-Week Highs And Lows
New Highs 135 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ AB Conservative Buffer BUFC 37.70 8,195
Chewy, Blackrock Fall; Spirit AeroSystems, Amedisys Rise, Monday, 7/1/2024
Amedisys on Track for Largest Percent Increase Since June 2023 -- Data Talk
Amedisys, Inc. (AMED) is currently at $95.12, up $3.33 or 3.62% --Would be highest close since May 30, 2024, when it closed at $96.01 --On pace for largest percent increase since June 5, 2023, when
Amedisys Gains as UnitedHealth to Sell Some Assets to Gain Regulatory Approval
Amedisys (NASDAQ:AMED) rose 3.3% after UnitedHealth (NYSE:UNH) late Friday disclosed an agreement with VitalCaring Group to sell some of the two companies' healthcare centers.
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
Comments
$Amedisys(AMED.US$ divergency with good fundamental Also gap so it looks good and risk to rewards is acceptable
1
$Inhibikase Therapeutics(IKT.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
$PharmaCyte Biotech(PMCB.US$
2
Read more
Kofi : Do u see it going above 100 ?